Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $69.00 at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI) had its target price boosted by HC Wainwright from $50.00 to $69.00 in a report issued on Tuesday, Marketbeat reports. They currently have a buy rating on the stock.

A number of other equities analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $57.00.

Greenwich LifeSciences Stock Up 4.1%

NASDAQ GLSI opened at $14.65 on Tuesday. The company has a 50-day moving average price of $22.93 and a 200-day moving average price of $24.55. The firm has a market capitalization of $215.06 million, a P/E ratio of -9.33 and a beta of 1.40. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in shares of Greenwich LifeSciences during the 2nd quarter worth $509,000. Bank of New York Mellon Corp increased its stake in Greenwich LifeSciences by 235.5% during the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock valued at $1,117,000 after purchasing an additional 32,657 shares in the last quarter. Virtu Financial LLC purchased a new position in Greenwich LifeSciences in the 4th quarter worth $605,000. Man Group plc purchased a new position in shares of Greenwich LifeSciences in the fourth quarter worth about $590,000. Finally, Sei Investments Co. purchased a new position in Greenwich LifeSciences during the 1st quarter worth approximately $627,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.